Probiotics are a potential treatment agent for IBD. In this study, the effects of probiotics on intestinal immune responses and gut microbiota in colitis were investigated. The result showed that L. plantarum AR113 and L. casei AR342 were 2–3 times more effective than other strains to alleviate epithelial damage indicators, improve colon length (+10–30%) and maintain the integrity of the epithelial barrier, as compared to DSS-treatment mice. The supplementation downregulated expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and upregulated that of the colonic anti-inflammatory cytokine (IL-10). The results strongly suggested that anti-inflammatory effect of probiotics is associated with the increase in HO-1 expression and the decrease in TLR4/MyD88/NF-κB pathway expression in mouse colonic tissues. Further, Microbiota analysis and the correlation of microbiota with colitis parameters revealed that the dysbiosis of gut microbiota induced by DSS treatment could be mitigated to a certain extent by supplementation with L. plantarum AR113.

益生菌是IBD的潜在治疗剂。在这项研究中，研究了益生菌对结肠炎肠道免疫反应和肠道菌群的影响。结果表明，植物乳杆菌AR113和干酪乳杆菌与DSS处理的小鼠相比，AR342在减轻上皮损伤指标，改善结肠长度（+ 10–30％）和维持上皮屏障完整性方面比其他品系高出2到3倍。补体下调了促炎细胞因子（TNF-α，IL-1β，IL-6）的表达，并上调了结肠抗炎细胞因子（IL-10）的表达。结果强烈表明，益生菌的抗炎作用与小鼠结肠组织中HO-1表达的增加和TLR4 / MyD88 /NF-κB途径表达的减少有关。此外，微生物群分析和微生物群与结肠炎参数的相关性表明，通过补充植物乳杆菌可以在一定程度上减轻DSS处理诱导的肠道微生物群的营养不良。 AR113。